Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
February 22, 2018Annals of OncologyOpen Access

Treatment effects measured by restricted mean survival time in trials of immune checkpoint inhibitors for cancer

View Full Paper
Ask AI
Bookmark
Share

Authors

FLFei LiangSZS. ZhangQWQ. Wang

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Liang et al. (2018) studied this question.

synapsesocial.com/papers/6a75086a01b447f0dadbfcfahttps://doi.org/10.1093/annonc/mdy075
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Comparison of Treatment Effects Measured by the Hazard Ratio and by the Ratio of Restricted Mean Survival Times in Oncology Randomized Controlled Trials2016 · 258 citations
  2. 2Ipilimumab Plus Sargramostim vs Ipilimumab Alone for Treatment of Metastatic Melanoma2014 · 358 citations
  3. 3Interpretability of Cancer Clinical Trial Results Using Restricted Mean Survival Time as an Alternative to the Hazard Ratio2017 · 256 citations
  4. 4Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma2011 · 4,497 citations
  5. 5Moving Beyond the Hazard Ratio in Quantifying the Between-Group Difference in Survival Analysis2014 · 836 citations